Emerillon Capital
VC Fund
Montréal, Canada
Emerillon Capital is a VC fund in Montréal focused on SaaS and Pharmaceutical. Based in Montreal, Emerillon Capital is a venture capital fund investing and supporting companies with strong technological expertise and positioned in promising sectors with strong potential for growth.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Emerillon Capital invests in
Stages Emerillon Capital invests in
Countries Emerillon Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
|
|||
4 more contacts available
Investment Focus
Industry
- SaaS 2 (29%)
- Pharmaceutical 2 (29%)
- CRM 1 (14%)
- Dental 1 (14%)
- Medical 1 (14%)
Stage
- Series A 2 (29%)
- Funding Round 2 (29%)
- Series B 1 (14%)
- Series D 1 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Ludovic ANDRÉ
Managing Director
|
Managing Director | Total investments: 13 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Founded in 2011 by brothers Gabriel and Bernard Robichaud, Panthera Dental is a leader in prosthetic implant solutions and dental sleep appliances. Employing more than 50, the Québec City firm also has an office in New Jersey. | Oct 03, 2017 | |
|
|
PreciThera, Inc. is a biotechnology company committed to the development of therapies for rare bone diseases using the combined application of computational technology and a deep understanding of disease pathology. The company focuses on heterogeneous genetic disorders that primarily manifest in bone dysfunction. In depth understanding of diseasemechanism will allow PreciThera’s targeted strategies to meaningfully impact both the skeletal symptoms as well as the extraskeletal issues found in these patients. | $26.3M / Series A / Jul 27, 2017 | |
|
|
Q4 is a SaaS platform that provides advanced communication and intelligence solutions to investor relations officers and the C-suite of public companies. With the goal of improving the effectiveness of investor relations through innovative, forward-thinking website solutions, the Q4 team designed an alternative approach to IR websites that putstorytelling first and emphasized intuitive corporate reporting.Q4 is a trusted partner to over 2,200 of the world’s largest brands. Q4’s comprehensive portfolio of IR communications, intelligence and corporate access solutions, supported by an industry-leading customer experience model, empower customers to build impactful and strategic IR programs | $22M / Series B / May 17, 2016 | |
|
|
Our vision is a world where intelligent machines work hand-in-hand with people to advance the collective intelligence of the human species and bring about positive social and economic impacts.We’re an early leader in using deep learning and deep reinforcement learning to solve language-understanding problems and in training machines to modeldecision-making capabilities of the human brain.Maluuba is backed by an accomplished team of leading investors and some of the most respected researchers in the fields of artificial intelligence and deep learning. We partner with the world’s largest organizations in communications, customer experience, technology, automotive and professional services. | $6.6M / Series A / Jan 20, 2016 | |
|
|
ScribbleLive is a content cloud provider that helps companies manage the lifecycle of their content. It provides global brands with the services and solutions they need to create premium content at scale. The company's managed services provide clients with program and campaign coverage including dashboards and program reporting. Its servicesoffered includes content strategy, creative services, implementation, integration, and IT support. ScribbleLive was founded in 2008 and is headquartered in Toronto, Ontario. | $25.6M / Series D / Sep 23, 2015 | |
|
|
GenePOC Inc. is a privately owned company, member of Debiopharm Group, that develops accurate and cost-effective molecular solutions to detect pathogen genes. GenePOC has developed a simple and stand-alone system for the prevention and early detection of infectious diseases based on a unique microfluidic technology. | Jan 13, 2015 | |
|
|
Searchlight Pharma aspires to become a leading Canadian-based specialty healthcare company through best-in class execution of the search, acquisition, commercialization, and focused development of innovative and unique specialty healthcare products that improve life-long human health and wellness. | Private Equity |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Emerillon Capital invest in?
Emerillon Capital invests primarily in SaaS, Pharmaceutical and CRM startups, most often at Series A and Funding Round stage. Most of the 7 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Emerillon Capital?
Public channels for Emerillon Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Emerillon Capital?
The team at Emerillon Capital includes Ludovic ANDRÉ (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!